The association between cytochrome P450-2D6 genotype and prescription of antiparkinsonian drugs in hospitalized psychiatric patients using antipsychotics: A retrospective follow-up study [4]

Journal of Clinical Psychopharmacology

Volumn 26, Issue 2, 2006, Pages 212-215

  Mulder, Hans ^a,b   Wilmink, Frederik W ^c   Belitser, Svetlana V ^a   Egberts, Antoine C G ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

^b Wilhelmina Ziekenhuis   (Netherlands)

^c GGZ Drenthe   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPARKINSON AGENT; BIPERIDEN; CHLORPROMAZINE; CLOZAPINE; CYTOCHROME P450 2D6; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; PIMOZIDE; QUETIAPINE; RISPERIDONE; SERTINDOLE; THIORIDAZINE; TRIHEXYPHENIDYL; ZUCLOPENTHIXOL;

ADULT; AGED; AKATHISIA; CONTROLLED STUDY; DRUG METABOLISM; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; FEMALE; FOLLOW UP; GENOTYPE; HOSPITAL PATIENT; HUMAN; LETTER; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; PARKINSONISM; POLYMERASE CHAIN REACTION; PRESCRIPTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RETROSPECTIVE STUDY; TARDIVE DYSKINESIA;

ANTIPARKINSON AGENTS; ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; CYTOCHROME P-450 CYP2D6; DRUG PRESCRIPTIONS; FEMALE; GENOTYPE; HOSPITALIZATION; HOSPITALS, PSYCHIATRIC; HUMANS; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; PRESCRIPTIONS, DRUG; RETROSPECTIVE STUDIES; RISK;

EID: 33646706571     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jcp.0000203599.50937.d4     Document Type: Letter

References (10)

1. Dahl ML. Cytochrome p450 phenotyping/genotyping in patients receiving antipsychotics: useful aid to prescribing? Clin Pharmacokinet. 2002;41(7):453-470.
2. Mulder H, Wilmink FW, Beumer TL, et al. The association between cytochrome P450 2D6 genotype and prescription patterns of antipsychotic and antidepressant drugs in hospitalized psychiatric patients: a retrospective follow-up study. J Clin Psychopharmacol. 2005;25(2):188-191.
3. Stuven T, Griese EU, Kroemer HK, et al. Rapid detection of CYP2D6 null alleles by long distance- and multiplex-polymerase chain reaction. Pharmacogenetics. 1996;6(5):417-421.
4. Lovlie R, Daly AK, Molven A, et al. Ultrarapid metabolizers of debrisoquine: characterization and PCR-based detection of alleles with duplication of the CYP2D6 gene. FEBS Lett. 1996;392(1):30-34.
5. Pinheiro JC, Bates DM. Mixed-effects Models in S and S-plus. Berlin: Springer; 2000.
6. Shao J, Tu D. The Jackknife and Bootstrap. Berlin: Springer; 1995.
7. Patsopoulos NA, Ntzani EE, Zintzaras E, et al. CYP2D6 polymorphisms and the risk of tardive dyskinesia in schizophrenia: a meta-analysis. Pharmacogenet Genomics. 2005;15(3):151-158.
8. Schillevoort I, De Boer A, Van der Weide J, et al. Antipsychotic-induced extrapyramidal syndromes and cytochrome P450 2D6 genotype: a case-control study. Pharmacogenetics. 2002;12(3):235-240.
9. Scordo MG, Spina E, Romeo P, et al. CYP2D6 genotype and antipsychotic-induced extrapyramidal side effects in schizophrenic patients. Eur J Clin Pharmacol. 2000;56:679-683.
10. Andreassen OA, MacEwan T, Gulbrandsen AK, et al. Non-functional CYP2D6 alleles and risk for neuroleptic-induced movement disorders in schizophrenic patients. Psychopharmacology. 1997;131(2):174-179.